Induction treatment of ANCA-associated vasculitis with a single dose of rituximab

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

(2013) Ulrich Specks et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels

(2012) Mark N. Lazarus et al.   RHEUMATOLOGY

Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine

(2011) C. Bartel et al.   CLINICAL NEPHROLOGY

The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation

(2011) T. Turner-Stokes et al.   RHEUMATOLOGY

Abnormalities of B cell subsets in patients with systemic lupus erythematosus

(2010) Thomas Dörner et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis

(2009) M. A. Little et al.   ANNALS OF THE RHEUMATIC DISEASES

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis

(2009) Rachel B. Jones et al.   ARTHRITIS AND RHEUMATISM

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE